{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T18:08:12Z","timestamp":1779991692402,"version":"3.53.1"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Prolactinomas are the most common functioning pituitary neuroendocrine tumors (PitNETs). In transgender women, gender-affirming hormone therapy (GAHT) usually combines high doses of estrogen and anti-androgen therapy, both of which can elevate serum prolactin levels. Whether GAHT influences tumor behavior in patients with pre-existing prolactinomas remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and methods<\/jats:title>\n                    <jats:p>Case report illustrating the clinical challenges in managing a prolactinoma in the context of GAHT initiation, combined with a systematic review of all published cases and available guidelines of GAHT in the prolactinoma context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 22-year-old female (46,XY; assigned male at birth) with untreated gender dysphoria and hypogonadism was diagnosed with a macroprolactinoma (39.9\u2005mm; serum prolactin 285 \u00d7 upper limit of normal (ULN)). Cabergoline therapy reduced prolactin levels to 27.3 \u00d7 ULN within one year. Pituitary apoplexy with acute visual field and acuity deterioration required emergency transsphenoidal debulking. Two months postoperatively, prolactin levels were 8.6 \u00d7 ULN with total hypopituitarism and small irresectable remnants. Initiation of estrogen therapy led to unexpected biochemical (128.4 \u00d7 ULN) and radiological progression despite cabergoline reintroduction and dose escalation, necessitating estrogen withdrawal to stabilize the disease. Subsequent radiotherapy allowed safe estrogen reintroduction. To date, 24 prolactinomas in transgender women (including this case) have been reported, most diagnosed after GAHT initiation and lacking baseline prolactin data. Current clinical guidelines provide no specific recommendations for pituitary tumors in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GAHT initiation might induce rapid progression and concomitant dopamine-agonist resistance in residual macroprolactinoma. Individualized, multidisciplinary management is needed. Development of dedicated clinical guidelines is essential to combine tumor control with gender-affirming care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag085","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:58:59Z","timestamp":1778673539000},"page":"694-714","source":"Crossref","is-referenced-by-count":0,"title":["Prolactinoma course and management in transgender women: case report and systematic review"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-7643","authenticated-orcid":false,"given":"Maaia Margo","family":"Jentus","sequence":"first","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]},{"name":"Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4956-4037","authenticated-orcid":false,"given":"Iris","family":"Pelsma","sequence":"additional","affiliation":[{"name":"Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]},{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria River","family":"van Trigt","sequence":"additional","affiliation":[{"name":"Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]},{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leontine","family":"Bakker","sequence":"additional","affiliation":[{"name":"Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]},{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jose","family":"Pouwels","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Medical Spectrum Twente , Enschede 7500 KA, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"van Furth","sequence":"additional","affiliation":[{"name":"Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]},{"name":"Department of Neurosurgery, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Verstegen","sequence":"additional","affiliation":[{"name":"Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]},{"name":"Department of Neurosurgery, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Morreau","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]},{"name":"Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-3594","authenticated-orcid":false,"given":"Nienke","family":"Biermasz","sequence":"additional","affiliation":[{"name":"Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]},{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"2026052813514880800_lvag085-B1","volume-title":"Endocrine and Neuroendocrine Tumours [Internet]","author":"WHO Classification of Tumours Editorial Board","year":"2022"},{"issue":"6","key":"2026052813514880800_lvag085-B2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026052813514880800_lvag085-B3","doi-asserted-by":"publisher","first-page":"9598","DOI":"10.1038\/s41598-025-90250-6","article-title":"Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations","volume":"15","author":"Andereggen","year":"2025","journal-title":"Sci Rep."},{"issue":"12","key":"2026052813514880800_lvag085-B4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2026052813514880800_lvag085-B5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/17446651.2020.1825075","article-title":"Endocrine treatment of transgender individuals: current guidelines and strategies","volume":"15","author":"Prince","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"11","key":"2026052813514880800_lvag085-B6","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society* clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"Suppl. 1","key":"2026052813514880800_lvag085-B7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgend Health"},{"issue":"3","key":"2026052813514880800_lvag085-B8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36484","article-title":"Gender-affirming hormone therapy: physical and sociopsychological effects, impact and satisfaction","volume":"15","author":"Santos","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"2026052813514880800_lvag085-B9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2265.1977.tb01338.x","article-title":"Serum prolactin and oestradiol levels at different stages of puberty","volume":"7","author":"Thorner","year":"1977","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"2026052813514880800_lvag085-B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031305","article-title":"Prolactin secretion in healthy adults is determined by gender, age and body mass index","volume":"7","author":"Roelfsema","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"2026052813514880800_lvag085-B11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1203\/00006450-197802000-00065","article-title":"Human prolactin during puberty and first menstrual cycles in girls","volume":"12","author":"Aubert","year":"1978","journal-title":"Pediatr Res."},{"issue":"1","key":"2026052813514880800_lvag085-B12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4274\/jpea.2025.389","article-title":"Pediatric hyperprolactinemia: clinical features, diagnostic groups, and treatment approaches: hyperprolactinemia in childhood","volume":"6","author":"Ayta\u00e7 Kaplan","year":"2025","journal-title":"J Pediatr Acad"},{"issue":"6","key":"2026052813514880800_lvag085-B13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1365-2265.1988.tb03849.x","article-title":"Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals","volume":"28","author":"Asscheman","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026052813514880800_lvag085-B14","volume-title":"Endotext [Internet]","author":"Scott","year":"2000"},{"key":"2026052813514880800_lvag085-B15","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad052","article-title":"Changes in laboratory results in transgender individuals on hormone therapy\u2014a retrospective study and practical approach","author":"Boekhout-Berends","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026052813514880800_lvag085-B16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/15532739.2020.1819505","article-title":"Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: a systematic review","volume":"21","author":"Wilson","year":"2020","journal-title":"Int J Transgend Health"},{"issue":"6","key":"2026052813514880800_lvag085-B17","doi-asserted-by":"publisher","DOI":"10.1111\/and.12666","article-title":"Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons","volume":"49","author":"Nota","year":"2017","journal-title":"Andrologia"},{"issue":"2","key":"2026052813514880800_lvag085-B18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2265.1985.tb01081.x","article-title":"Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction","volume":"22","author":"Gooren","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2026052813514880800_lvag085-B19","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/brain\/awy108","article-title":"The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment","volume":"141","author":"Nota","year":"2018","journal-title":"Brain"},{"issue":"10","key":"2026052813514880800_lvag085-B20","doi-asserted-by":"publisher","first-page":"e3936","DOI":"10.1210\/clinem\/dgab427","article-title":"Toward a lowest effective dose of cyproterone acetate in trans women: results from the ENIGI study","volume":"106","author":"Kuijpers","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026052813514880800_lvag085-B21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/lgbt.2016.0190","article-title":"Transient elevated Serum prolactin in trans women is caused by cyproterone acetate treatment","volume":"4","author":"Defreyne","year":"2017","journal-title":"LGBT Health"},{"issue":"7","key":"2026052813514880800_lvag085-B22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4158\/EP-2018-0101","article-title":"Prolactin levels do not rise among transgender women treated with estradiol and spironolactone","volume":"24","author":"Bisson","year":"2018","journal-title":"Endocr Pract"},{"issue":"8","key":"2026052813514880800_lvag085-B23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.4158\/EP-2020-0032","article-title":"Differential endocrine and metabolic effects of testosterone suppressive agents in transgender women","volume":"26","author":"Sofer","year":"2020","journal-title":"Endocr Pract"},{"issue":"6","key":"2026052813514880800_lvag085-B24","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/and.12317","article-title":"Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy","volume":"47","author":"Cunha","year":"2015","journal-title":"Andrologia"},{"issue":"2","key":"2026052813514880800_lvag085-B25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12020-020-02563-3","article-title":"Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment","volume":"72","author":"Raven","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"2026052813514880800_lvag085-B26","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0070","article-title":"Chromosomal alteration patterns in PitNETs: massive losses in aggressive tumors","volume":"32","author":"Jentus","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2026052813514880800_lvag085-B27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1210\/jcem-66-2-444","article-title":"Estrogen-induced prolactinoma in a man","volume":"66","author":"Gooren","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2026052813514880800_lvag085-B28","doi-asserted-by":"publisher","first-page":"bcr0220091589","DOI":"10.1136\/bcr.02.2009.1589","article-title":"Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages","volume":"2009","author":"Bunck","year":"2009","journal-title":"BMJ Case Rep"},{"issue":"3","key":"2026052813514880800_lvag085-B29","doi-asserted-by":"publisher","first-page":"1097.e13","DOI":"10.1016\/j.fertnstert.2010.01.076","article-title":"Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual","volume":"94","author":"Garc\u00eda-Malpartida","year":"2010","journal-title":"Fertil Steril"},{"issue":"5","key":"2026052813514880800_lvag085-B30","first-page":"562","article-title":"Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study","volume":"118","author":"Kovacs","year":"1994","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"2026052813514880800_lvag085-B31","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1210\/jcem.81.9.8784065","article-title":"Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient","volume":"81","author":"Serri","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026052813514880800_lvag085-B32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1023\/A:1018638715498","article-title":"Endocrine therapy of transsexualism and potential complications of long-term treatment","volume":"27","author":"Futterweit","year":"1998","journal-title":"Arch Sex Behav"},{"issue":"Supplement 1","key":"2026052813514880800_lvag085-B33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/01.qai.0000479701.54420.44","article-title":"P-B1 Prolactinoma in a transgender Male-To-Female HIV positive adult-A rare occurrence & A therapeutic dilemma","volume":"71","author":"Jehangir","year":"2016","journal-title":"JAIDS J Acquired Immune Deficiency Syndromes"},{"issue":"Supplement_1","key":"2026052813514880800_lvag085-B34","doi-asserted-by":"publisher","first-page":"A795","DOI":"10.1210\/jendso\/bvab048.1617","article-title":"Prolactinoma in a male to female transgender woman on gender affirming hormone therapy","volume":"5","author":"Harned","year":"2021","journal-title":"J Endocr Soc."},{"issue":"Supplement_1","key":"2026052813514880800_lvag085-B35","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.1379","article-title":"MON-048 Proactive on prolactin: hyperprolactinemia management in transgender patients","volume":"9","author":"Chow","year":"2025","journal-title":"J Endocr Soc."},{"issue":"8","key":"2026052813514880800_lvag085-B36","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf120","article-title":"Prolactinoma resection in a transgender woman on gender-affirming hormone therapy","volume":"3","author":"Gersey","year":"2025","journal-title":"JCEM Case Rep"},{"issue":"8","key":"2026052813514880800_lvag085-B37","first-page":"1260","article-title":"Endocrine management of transsexual. Hormonal profiles of serum prolactin, testosterone, and estradiol","volume":"80","author":"Futterweit","year":"1980","journal-title":"N Y State J Med"},{"issue":"3","key":"2026052813514880800_lvag085-B38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1530\/EJE-08-0289","article-title":"Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones","volume":"159","author":"Mueller","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2026052813514880800_lvag085-B39","volume-title":"Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People","author":"UCSF Gender Affirming Health Program DoFaCM, University of California San Francisco","year":"2016","edition":"2nd ed"},{"key":"2026052813514880800_lvag085-B40","author":"Ontario"},{"issue":"3","key":"2026052813514880800_lvag085-B41","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40618-021-01694-2","article-title":"SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people","volume":"45","author":"Fisher","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"2026052813514880800_lvag085-B42","volume-title":"Medical Care of Trans and Gender Diverse Adults","author":"Thompson","year":"2021"},{"key":"2026052813514880800_lvag085-B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2024.08.003","article-title":"Endocrine management of transgender adolescents: expert consensus of the French society of pediatric endocrinology and diabetology working group","author":"Brezin","year":"2024;0929-693(24)00176-3","journal-title":"Arch Pediatr"},{"key":"2026052813514880800_lvag085-B44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1608108","article-title":"Approach to prolactin monitoring and hyperprolactinaemia in transgender and gender-diverse individuals undergoing gender affirming hormone therapy","volume":"16","author":"Nolan","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026052813514880800_lvag085-B45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","article-title":"The epidemiology of prolactinomas","volume":"8","author":"Ciccarelli","year":"2005","journal-title":"Pituitary"},{"key":"2026052813514880800_lvag085-B46","author":"CEU F"},{"issue":"7","key":"2026052813514880800_lvag085-B47","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1210\/jcem.82.7.4088","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026052813514880800_lvag085-B48","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1055\/s-0037-1615748","article-title":"Comparison of male and female prolactinoma patients requiring surgical intervention","volume":"79","author":"Yoo","year":"2018","journal-title":"J Neurol Surg B Skull Base"},{"key":"2026052813514880800_lvag085-B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2019.108496","article-title":"New insights into progesterone actions on prolactin secretion and prolactinoma development","volume":"152","author":"Camilletti","year":"2019","journal-title":"Steroids"},{"key":"2026052813514880800_lvag085-B50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/978-3-642-80859-3_7","volume-title":"Androgens II and Antiandrogens\/Androgene II und Antiandrogene","author":"Gr\u00e4f","year":"1974"},{"issue":"5603","key":"2026052813514880800_lvag085-B51","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/266641a0","article-title":"Prolactin\u2013progesterone antagonism in self regulation of prolactin receptors in the mammary gland","volume":"266","author":"Djiane","year":"1977","journal-title":"Nature"},{"issue":"3","key":"2026052813514880800_lvag085-B52","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3390\/ijms23031633","article-title":"Lactational amenorrhea: neuroendocrine pathways controlling fertility and bone turnover","volume":"23","author":"Calik-Ksepka","year":"2022","journal-title":"Int J Mol Sci."},{"key":"2026052813514880800_lvag085-B53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.594370","article-title":"The interplay between prolactin and reproductive system: focus on uterine pathophysiology","volume":"11","author":"Auriemma","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026052813514880800_lvag085-B54","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/13685530400004199","article-title":"Progesterone: the forgotten hormone in men?","volume":"7","author":"Oettel","year":"2004","journal-title":"Aging Male"},{"issue":"1","key":"2026052813514880800_lvag085-B55","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.brainresrev.2005.10.005","article-title":"Does male sexual behavior require progesterone?","volume":"51","author":"Andersen","year":"2006","journal-title":"Brain Res Rev."},{"issue":"4","key":"2026052813514880800_lvag085-B56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/a-0859-1144","article-title":"Unveiling the role of prolactin and its receptor in male reproduction","volume":"51","author":"Raut","year":"2019","journal-title":"Horm Metab Res"},{"key":"2026052813514880800_lvag085-B57","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1015520","article-title":"Metabolic effects of prolactin","volume":"13","author":"Pirchio","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2026052813514880800_lvag085-B58","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.3390\/ijms26104644","article-title":"ARID1A and its impact across the hallmarks of cancer","volume":"26","author":"Kearns","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026052813514880800_lvag085-B59","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.1016\/j.wneu.2018.09.196","article-title":"Hypoxia-inducible factor 1\u03b1 and AT-rich interactive domain-containing protein 1A expression in pituitary adenomas: association with pathological, clinical, and radiological features","volume":"121","author":"Kinali","year":"2019","journal-title":"World Neurosurg"},{"issue":"4","key":"2026052813514880800_lvag085-B60","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12022-019-09587-0","article-title":"The genomic landscape of sporadic prolactinomas","volume":"30","author":"De Sousa","year":"2019","journal-title":"Endocr Pathol"},{"issue":"1","key":"2026052813514880800_lvag085-B61","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.18632\/aging.202304","article-title":"Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype","volume":"13","author":"Chen","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"2026052813514880800_lvag085-B62","doi-asserted-by":"publisher","first-page":"e1833","DOI":"10.1210\/clinem\/dgae652","article-title":"The changing treatment paradigm for prolactinoma-A prospective series of 100 consecutive neurosurgical cases","volume":"110","author":"van Trigt","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag085\/68288660\/lvag085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/5\/694\/68288660\/lvag085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/5\/694\/68288660\/lvag085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T17:51:54Z","timestamp":1779990714000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/194\/5\/694\/8678437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag085","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,30]]}}}